Amneal Pharmaceuticals (AMRX) Stock

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.19 per share a year ago.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Reports Third Quarter 2024 Financial Results.

Invest in stocks of AMRX, CRON, CSV, BFST and APH to tap their high-efficiency levels.

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

On top of their cheap price tags, Wall Street analysts are high on all of these stocks and their improving earnings outlooks earn them strong Zacks Ranks.

Here is how Amneal Pharmaceuticals (AMRX) and Astrazeneca (AZN) have performed compared to their sector so far this year.

AMRX stock gains 29.3% in a month due to the FDA's approval of Parkinson's Disease drug, Crexont.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.